Biote Corp. 2025 Annual Report: Key Highlights and Investor Insights

Overview

Biote Corp. has released its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. The company, headquartered in Irving, Texas, specializes in medicinal chemicals and botanical products, and operates in the life sciences sector. The report provides an in-depth look at Biote’s business operations, financial position, risk factors, and regulatory environment. Below, we detail the most crucial information for investors and shareholders, especially points that may impact the company’s share price.

Key Financial and Operational Highlights

• Stock Information: As of March 11, 2026, Biote had 32,300,867 shares of Class A common stock and 7,249,879 shares of Class V voting stock, both with a par value of \$0.0001 per share, outstanding. The Class A common stock trades under the symbol BTMD on Nasdaq.
• Market Value: As of June 30, 2025, the aggregate market value of the common stock held by non-affiliates was reported as “approximately” (specific value not disclosed in extract). This figure is used to assess the company’s public float and could affect market liquidity and valuation.
• Reporting Status: Biote is a “smaller reporting company” and an “emerging growth company,” which may allow it to take advantage of certain reduced disclosure requirements and extended transition periods for new accounting standards. However, Biote did not elect to use the extended transition period for complying with new or revised financial accounting standards.
• Internal Controls: Biote disclosed that its internal controls over financial reporting do not fully meet the standards of Section 404 of the Sarbanes-Oxley Act. A material weakness led to the restatement of previously issued financial statements. This issue could impair Biote’s ability to produce timely and accurate financial statements and comply with regulations, which is a significant red flag for investors.
• Nasdaq Listing: The report warns that if Biote is unable to maintain its listing on Nasdaq, selling Class A common stock in the public market could become more difficult, potentially impacting liquidity and share price.
• Dividend Policy: There are no current plans to pay cash dividends on Class A common stock for the foreseeable future. Investors seeking income will need to rely on potential price appreciation.
• Capital Requirements: Biote may require additional capital to support business growth. If such capital is not available or is only available via dilution of existing shareholders, this could negatively affect share value.
• Anti-Takeover Provisions: The Charter and Bylaws, as well as Delaware law, contain anti-takeover provisions that could impair a takeover attempt, potentially affecting shareholder value in the event of acquisition interest.
• Insider and Incentive Plan Dilution: Future sales by the company or its stockholders, the issuance of rights to purchase Class A common stock, and exercises under the Incentive Plan and Employee Stock Purchase Plan could dilute percentage ownership and cause share price decline.

Summary of Risks and Regulatory Issues

• Regulatory Oversight: Biote operates in an industry with heavy regulatory oversight. The report specifically notes that if the FDA or other regulatory bodies implement recommendations from the National Academies of Sciences, Engineering, and Medicine regarding compounded bioidentical hormones, it could severely impact Biote-certified practitioners’ ability to use certain hormone pellets, which would have a substantial negative impact on revenue and business operations.
• Material Weakness in Financial Controls: The restatement of previously issued financial statements due to a material weakness is particularly important. It raises concerns about the reliability of past financial reports and signals ongoing risk in financial reporting accuracy.
• Growth Versus Profitability: The company states it is focusing on growth, which may negatively impact near-term results of operations. Investors should be aware that Biote’s strategy may prioritize long-term expansion over short-term profitability.
• Competition: Biote faces significant competition in its industry. Failure to compete effectively may result in lower market penetration and share, negatively affecting financial condition and results.
• Intellectual Property: The ability to protect intellectual property is highlighted as a critical factor for success.
• Geographical Expansion: The inability to profitably expand into new markets and maintain profitability in existing markets is identified as a risk.
• Economic and Market Uncertainties: The report lists exchange and interest rates, and other macroeconomic factors as risks to future performance.
• Potential for Dilution: Future sales of stock or perception thereof, as well as exercises of registration rights, may result in further dilution and share price pressure.

Other Investor-Relevant Information

• Business Focus: Biote’s core business consists of the Biote Method and Biote-branded dietary supplements. Success is dependent on market acceptance among clinics, practitioners, and patients.
• Proxy Statement Incorporation: Portions of the proxy statement for the 2025 annual meeting are incorporated by reference in Part III of the 10-K, which may include executive compensation, director information, and more.

Potential Price-Sensitive Issues

Material Weakness in Financial Controls: This is a major issue for investors and could lead to negative sentiment, increased volatility, and regulatory scrutiny.
Regulatory Risk: Implementation of the NASEM recommendations for compounded hormones could materially impact Biote’s business model and revenues.
Nasdaq Listing Risk: Potential delisting risk could affect liquidity and share price.
Growth-Focused Strategy: Short-term profitability may be sacrificed for long-term expansion.
Future Dilution: Incentive plans and potential capital raises could dilute existing shareholders.

Conclusion

Biote Corp.’s annual report highlights both opportunities and significant risks. Investors should pay close attention to regulatory developments, the company’s internal control issues, competitive landscape, and potential for equity dilution. These factors have the potential to materially affect Biote’s share value and should be considered in any investment decision.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with financial advisors before making investment decisions. The information is based on Biote Corp.’s 2025 Annual Report and may be subject to change or revision. Past performance and forward-looking statements are not guarantees of future results. Investing in stocks involves risk, including loss of principal.

View biote Corp. Historical chart here